https://www.selleckchem.com/products/Taurine.html
The prevalence of multiple myeloma is increasing and there is a need to evaluate escalating therapy costs (Canadian Cancer Statistics A, 202. The MYX.1 phase II trial showed that high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone (wKCD) is efficacious in relapsed and refractory disease. We conducted a descriptive cost analysis, from the perspective of the Canadian public healthcare system, using trial data. The primary outcome was the mean total cost per patient. Resource utilization data were collected from all 75 tria
Like
Comment
Share
